ATE442362T1 - Pyridylcyanoguanidin verbindungen - Google Patents

Pyridylcyanoguanidin verbindungen

Info

Publication number
ATE442362T1
ATE442362T1 AT02771630T AT02771630T ATE442362T1 AT E442362 T1 ATE442362 T1 AT E442362T1 AT 02771630 T AT02771630 T AT 02771630T AT 02771630 T AT02771630 T AT 02771630T AT E442362 T1 ATE442362 T1 AT E442362T1
Authority
AT
Austria
Prior art keywords
halogen
alkylcarbonyl
aminoalkyl
formyl
alkoxycarbonyl
Prior art date
Application number
AT02771630T
Other languages
English (en)
Inventor
Fredrik Bjirkling
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Application granted granted Critical
Publication of ATE442362T1 publication Critical patent/ATE442362T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02771630T 2001-05-24 2002-05-24 Pyridylcyanoguanidin verbindungen ATE442362T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29292801P 2001-05-24 2001-05-24
US29292701P 2001-05-24 2001-05-24
PCT/DK2002/000353 WO2002094813A1 (en) 2001-05-24 2002-05-24 Novel pyridyl cyanoguanidine compounds

Publications (1)

Publication Number Publication Date
ATE442362T1 true ATE442362T1 (de) 2009-09-15

Family

ID=26967641

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02771630T ATE442362T1 (de) 2001-05-24 2002-05-24 Pyridylcyanoguanidin verbindungen

Country Status (17)

Country Link
US (2) US7304066B2 (de)
EP (1) EP1397355B1 (de)
JP (1) JP4429607B2 (de)
KR (1) KR20030097897A (de)
CN (1) CN1247570C (de)
AT (1) ATE442362T1 (de)
BR (1) BR0209930A (de)
CA (1) CA2447021C (de)
CZ (1) CZ20033190A3 (de)
DE (1) DE60233656D1 (de)
ES (1) ES2328799T3 (de)
HU (1) HUP0400021A3 (de)
IL (1) IL158574A0 (de)
MX (1) MXPA03010669A (de)
PL (1) PL366459A1 (de)
RU (1) RU2292344C2 (de)
WO (1) WO2002094813A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1556053A4 (de) 2002-10-31 2006-04-19 Amgen Inc Entzündungshemmende mittel
WO2005075436A2 (en) * 2004-02-05 2005-08-18 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
TW200616967A (en) 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
US8053446B2 (en) 2004-12-22 2011-11-08 Leo Pharma A/S Cyanoguanidine compounds
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
NZ563687A (en) 2005-06-30 2011-07-29 Smithkline Beecham Corp 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-[2-(1-methylethyl)-2,3-dihydro-1H-isoindol-5-yl]-1H-indole-7-carboxamide for inhibiting IKK2 (aka IKKbeta)
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
CN102186822A (zh) 2008-08-29 2011-09-14 顶标公司 新脲和硫脲衍生物
WO2010088842A1 (zh) * 2009-02-06 2010-08-12 天津和美生物技术有限公司 含有吡啶基氰基胍的药物组合物及其制备和应用
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
EP2453883A1 (de) 2009-07-17 2012-05-23 Topo Target A/S Verfahren zur prognose des nutzens der verabreichung von nikotinsäure bzw. einem vorläufer oder prodrug daraus zur minderung des schweregrades der nebenwirkungen einer krebsbehandlung mit nikotinamid-phosphoribosyltransferase-hemmern
WO2011095027A1 (zh) * 2010-02-04 2011-08-11 天津和美生物技术有限公司 吡啶基氰基胍衍生物
CN102740850B (zh) * 2010-02-04 2014-04-02 天津和美生物技术有限公司 吡啶基氰基胍衍生物
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
WO2011121055A1 (en) 2010-03-31 2011-10-06 Topotarget A/S Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
AR082886A1 (es) * 2010-09-03 2013-01-16 Forma Therapeutics Inc Compuestos y composiciones farmaceuticas que los contienen
JP2013540781A (ja) 2010-10-26 2013-11-07 ティエンジン ホーメイ バイオ−テック カンパニー, リミテッド N−(6−(4−クロロフェノキシ)ヘキシル)−n’−シアノ−n’’−(4−ピリジル)グアニジンの結晶多形とその製造及び使用
CA2820763A1 (en) * 2010-12-09 2012-06-14 Radikal Therapeutics Inc. Multifunctional nitroxide derivatives and uses thereof
EP2836216B1 (de) * 2012-04-13 2022-06-08 Epizyme, Inc. Kombinationstherapie zur behandlung von krebs
KR101656663B1 (ko) 2015-07-27 2016-09-13 충남대학교산학협력단 암 예방 및 치료용 조성물
CN112585136B (zh) 2018-08-17 2024-06-25 诺华股份有限公司 作为smarca2/brm atp酶抑制剂的脲化合物和组合物
CN110734405A (zh) * 2019-11-11 2020-01-31 华东数字医学工程研究院 一种n-(6-氨己基)-n’-甲基-2,2’-联咪唑的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696140A (en) * 1992-09-15 1997-12-09 Leo Pharmaceutical Products Ltd. N-cyano-N'-pyridylguanidines as serotonin antagonists
GB9219472D0 (en) 1992-09-15 1992-10-28 Leo Pharm Prod Ltd Chemical compounds
GB9711119D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711124D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711123D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711125D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711122D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
US7129043B1 (en) * 1998-10-22 2006-10-31 Duke University Methods of screening for risk of proliferative disease and methods for the treatment of proliferative disease
WO2000061561A1 (en) * 1999-04-09 2000-10-19 Shionogi Bioresearch Corp. Cyanoguanidine compounds
AU4076500A (en) * 1999-04-09 2000-11-14 Shionogi Bioresearch Corp. (n)-substituted cyanoguanidine compounds
US6645968B2 (en) 1999-08-03 2003-11-11 Abbott Laboratories Potassium channel openers
MXPA02001207A (es) 1999-08-03 2002-07-30 Abbott Lab Abridores de canal de potasio.

Also Published As

Publication number Publication date
BR0209930A (pt) 2004-03-30
JP4429607B2 (ja) 2010-03-10
CN1247570C (zh) 2006-03-29
PL366459A1 (en) 2005-02-07
IL158574A0 (en) 2004-05-12
JP2005508859A (ja) 2005-04-07
US20080090842A1 (en) 2008-04-17
CZ20033190A3 (cs) 2004-06-16
HUP0400021A2 (hu) 2004-04-28
ES2328799T3 (es) 2009-11-18
RU2003137007A (ru) 2005-04-20
MXPA03010669A (es) 2004-07-01
EP1397355A1 (de) 2004-03-17
KR20030097897A (ko) 2003-12-31
HUP0400021A3 (en) 2008-03-28
WO2002094813A1 (en) 2002-11-28
CN1509283A (zh) 2004-06-30
US20040220408A1 (en) 2004-11-04
CA2447021C (en) 2010-08-10
US7304066B2 (en) 2007-12-04
EP1397355B1 (de) 2009-09-09
RU2292344C2 (ru) 2007-01-27
CA2447021A1 (en) 2002-11-28
US7807682B2 (en) 2010-10-05
DE60233656D1 (de) 2009-10-22
HK1066216A1 (en) 2005-03-18

Similar Documents

Publication Publication Date Title
DE60233656D1 (de) Pyridylcyanoguanidin verbindungen
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
ATE302775T1 (de) Carbolinderivate
MY135841A (en) Novel benzodioxoles
IL176110A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
MY138737A (en) N3-substituted imidazopyridine c-kit inhibitors
BG106586A (en) Pyrazolopyramidines as therapeutic agents
MXPA05009359A (es) Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6.
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
IS6902A (is) N-setin heterósýklísk NMDA/NR2B mótlyf sem ekki eru arýl
PL377285A1 (pl) Podstawione pochodne pirolo-pirazolowe jako inhibitory kinazy
IL189694A0 (en) Biphenyl derivatives and their use in treating hepatitis c
IL164511A0 (en) Heterocyclic compounds
MY144622A (en) Agents for preventing and treating disorders involving modulation of the ryr receptors
MY139571A (en) Indolyl derivatives as liver-x-receptor modulators
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
ATE346067T1 (de) Carbolinderivate
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
MXPA04006184A (es) Compuestos derivados de 1h-pirazolilo, para el uso en enfermedades asociadas con el receptor 5-ht2c.
AU2002213421A1 (en) Condensed pyridoindole derivatives
EA200501703A1 (ru) Применение производных азетидинкарбоксамида в терапии
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
ATE297904T1 (de) Halo-alkoxycarbonylverbindungen
MXPA02012470A (es) Inhibidores de fosfodiesterasa especificos para gmp ciclico.
MXPA03002909A (es) Compuestos quimicos.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties